Tevogen Bio Leverages Microsoft Partnership To Deliver Machine Learning Based Target Identification To Address HPV, Advancing TVGN 920
Tevogen Bio Leverages Microsoft Partnership To Deliver Machine Learning Based Target Identification To Address HPV, Advancing TVGN 920
- Tevogen Bio begins pre-clinical effort for TVGN 920, signaling the start of its oncology treatment pipeline.
- Tevogen Bio created a data set containing known proteins in the HPV genome to identify targets, accelerating the pre-clinical process.
- 5.5 million women per year have HPV 16/18; of these 200,000 women per year are diagnosed with high grade dysplasia.
- Tevogen Bio開始針對TVGN 920進行臨床前努力，標誌着其腫瘤治療流程的開始。
- Tevogen Bio創建了一個包含HPV基因組中已知蛋白質的數據集，以識別目標，加快臨床前進程。
- 每年有550萬名婦女患有HPV 16/18型病毒；其中每年有20萬名婦女被診斷患有高級別畸形症。
WARREN, N.J., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, recently announced its Artificial Intelligence effort, Tevogen.AI, had partnered with Microsoft (NASDAQ:MSFT), the world's leading AI company.
新澤西州華倫，2024年11月5日（環球新聞社）--Tevogen Bio（"Tevogen"或"Tevogen Bio Holdings Inc."）（納斯達克:TVGN），一家處於臨床階段的專業免疫療法生物技術公司，正在開發用於治療傳染病和癌症的非定製、基因未經修改的T細胞治療藥物。最近，其人工智能項目Tevogen.AI與微軟（納斯達克:MSFT）合作，微軟是全球領先的AI公司。
Using Microsoft's suite of advanced tools, Tevogen Bio is proactively investigating potential treatments for HPV to create a portfolio of oncology products. The company has developed a dataset of proteins from the HPV genome and is identifying cytotoxic T cell (CTL) targets to choose for a clinical trial for TVGN 920, its first oncology product. Through Tevogen's proprietary ExacTcell technology, where CTLs are trained to detect specific targets and then expanded, the company aims to be prepared to deliver an HPV-specific CTL treatment.
利用微軟一系列先進工具，Tevogen Bio正在積極研究HPV的潛在治療方案，以創建一系列腫瘤學產品組合。該公司已經開發了一組來自HPV基因組的蛋白質數據集，並且正在鑑定細胞毒性T細胞（CTL）的目標，以選擇用於TVGN 920的臨床試驗，這是其首個腫瘤學產品。通過Tevogen的專有ExacTcell技術，該技術訓練CTLs以檢測特定目標，然後進行擴展，該公司旨在準備提供特定HPV的CTL治療。
譯文內容由第三人軟體翻譯。
